Dabrafenib and Trametinib Combination as a Neoadjuvant Strategy in BRAF-positive Anaplastic Thyroid Cancer

NCT04739566 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Lack of funding

Conditions

Thyroid Gland Anaplastic Carcinoma

Interventions

DRUG: Dabrafenib
DRUG: Trametinib

Sponsor

Saint Petersburg State University, Russia